Related Experiment Video

Updated: Sep 25, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.4K

Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies

Jeanne Tie1, Jayesh Desai

  • 1Ludwig Colon Cancer Initiative Laboratory, Ludwig Institute for Cancer Research, Parkville, VIC, Australia.

Targeted Oncology
|August 15, 2014
PubMed

Insights

BRAF mutations drive colorectal cancer progression, especially in metastatic cases. Targeting BRAFV600E shows promise, with new combination therapies emerging to overcome resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Colorectal cancer (CRC) progression is linked to specific molecular defects.
  • The mitogen-activated protein kinase (MAPK) pathway is crucial in CRC.
  • BRAF mutations are present in 10% of CRC cases, particularly metastatic disease.

Purpose of the Study:

  • To review the molecular and clinical aspects of BRAF-mutant CRC.
  • To discuss the prognostic and predictive significance of BRAFV600E mutations.
  • To explore targeted therapies and resistance mechanisms for BRAF-mutant CRC.

Main Methods:

  • Literature review of studies on BRAF mutations in colorectal cancer.
  • Analysis of clinical trial data for BRAF-targeted therapies.
  • Examination of preclinical research on resistance mechanisms.

Main Results:

  • BRAFV600E mutation has significant prognostic and predictive value in CRC.
  • BRAF-targeted therapies have shown initial clinical activity.
  • Resistance to BRAF inhibition is a key challenge, prompting combination strategies.

Conclusions:

  • Understanding BRAF mutations is vital for CRC treatment.
  • Targeting BRAFV600E is a valid therapeutic strategy.
  • Combination therapies are essential for overcoming resistance and improving outcomes.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

18.1K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...